Compare ACAD & KBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACAD | KBH |
|---|---|---|
| Founded | 1993 | 1957 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.8B |
| IPO Year | 2000 | 1994 |
| Metric | ACAD | KBH |
|---|---|---|
| Price | $22.18 | $52.48 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 22 | 14 |
| Target Price | $30.55 | ★ $56.17 |
| AVG Volume (30 Days) | ★ 1.4M | 1.0M |
| Earning Date | 05-06-2026 | 03-24-2026 |
| Dividend Yield | N/A | ★ 1.84% |
| EPS Growth | ★ 69.12 | N/A |
| EPS | ★ 2.30 | 0.52 |
| Revenue | $726,437,000.00 | ★ $4,547,002,000.00 |
| Revenue This Year | $18.80 | N/A |
| Revenue Next Year | $11.70 | $9.23 |
| P/E Ratio | ★ $9.87 | $104.74 |
| Revenue Growth | ★ 40.45 | N/A |
| 52 Week Low | $14.20 | $48.17 |
| 52 Week High | $28.35 | $68.71 |
| Indicator | ACAD | KBH |
|---|---|---|
| Relative Strength Index (RSI) | 50.95 | 43.61 |
| Support Level | $21.51 | $48.89 |
| Resistance Level | $22.97 | $52.79 |
| Average True Range (ATR) | 0.66 | 1.38 |
| MACD | 0.08 | 0.30 |
| Stochastic Oscillator | 66.67 | 28.77 |
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
KB Home is an American construction company that focuses on residential construction in the United States. The company builds single-family homes and communities across different geographical segments which include the West Coast which also derives the majority of the revenue, Southwest, Central, and Southeast. The company operates in several markets and focuses on first-time and move-up homebuyers. It also invests in land acquisition and development to support future building activities and is also engaged in financial services operations which includes providing mortgage banking services through its joint venture with a third party.